Martin D. Chapman, PhD, is President and CEO of Indoor Biotechnologies, a company he founded and spun out of the University of Virginia. Indoor Biotechnologies is a biotechnology manufacturing company which produces molecular products for allergy and asthma research. The company has bio-manufacturing and R&D facilities in Charlottesville, Cardiff, UK, and Bangalore, India, and distributors in Japan, Korea and China.
InBio products include purified allergens for research and diagnostic use; test kits for assessing environmental allergen exposure; and Ventia, a consumer test for dust mites that is sold on Amazon.com. The company has an extensive range of laboratory services for allergen and food testing and provides contract research services. InBio has a patented dust collection device, DUSTREAM®, and has a single state-of-the-art test, MARIA®, for all common allergens in homes.
In 2015, InBio completed construction of a $2.7MM bio-manufacturing and research facility in downtown Charlottesville, which also includes the CREATE art gallery/exhibition space and the Silk Mill Salon, a conference suite for 50 people. InBio supports emerging biotechnology and technology-based companies in Central Virginia with a focus on innovation, entrepreneurship and economic development.